Aspire incubates multiple companies and uses a rigorous approach to advance ventures quickly from concept to market.
Appmobi is a product-stage venture that offers cognitive cybersecurity tools and services to secure mobile applications and IoT devices. Security Kit™ helps developers secure developed apps at the code level from the start – making it as easy on developers as adding a plugin. Protection Center™ offers IT management easily implemented mobile application activity monitoring, threat detection, and threat remediation in a single easy-to-use solution that complements any existing EMM solutions currently in place.
Connexion Health is a prototype-stage venture that leverages the best of what technology has to offer today to transform healthcare from something endured only when necessary into a pleasurable and desirable patient experience. Connexion Health has recently introduced the Connexion, an AI-powered technology platform equipped with a multitude of powerful sensors that can be harnessed for a host of new health applications. Connexion Health has also secured the contract to provide the entire innovation technology package to Clio Health, a smart hospital and community health center of the future, being piloted in Lancaster, PA.
DISFA is a growth stage venture that is a leader in advanced predictive analytics for the Financial Industry. DISFA’s competitive advantage is the proprietary development and utilization of machine learning environments, pattern recognition, and the automatic generation of adaptive trading systems. DISFA’s unique platform provides its clients with dynamic alpha generation strategies, asset allocation models, and risk management tools and solutions.
MedStatix is a product-stage venture focused on improving the patient experience with an industry-leading platform for measuring patient satisfaction with real-time feedback and analysis. With more than 2.3 million completed patient experience surveys across the nation, MedStatix holds the largest and fastest growing database of patient experience data. Leveraging that data, MedStatix is also developing a provider match tool that generates personalized provider recommendations for patients.
Nanodyne is a prototype-stage venture and developer of breakthrough microfluidic sensor technology that will change the way we monitor health and manage disease. By leveraging a proprietary graphene extraction method, Nanodyne is developing liquid graphene sensors that can be worn on the skin to measure blood glucose, blood alcohol, and mineral levels, giving consumers a low-cost, noninvasive way to continuously monitor their health.
Tempo Health is a prototype-stage venture that offers a smarter way to manage diabetes. Using Aspire’s A2I platform, Tempo Health’s Rhythm™ system personalizes blood glucose predictions without invasive and expensive hardware for type 1 diabetic patients. A recent observational trial with the Diabeter Clinic, a top-performing Netherlands-based treatment center for type 1 diabetics, has shown Tempo Health’s AI-powered system to be capable of maintaining patients’ time in healthy blood sugar ranger more effectively than a dedicated team of endocrinologists.
VitaVista is a concept-stage venture that uses A2I to accelerate and improve medical imaging enhancement, augmentation, and analysis for use in decision support systems. VitaVista’s AI-powered solutions enable physicians and imaging specialists to make more accurate diagnoses with increased operational efficiency.
Wylei is a growth-stage venture that uses machine learning to help marketers achieve true 1-to-1 personalization in any type of digital message at scale. Wylei is an emerging leader in the marketing automation space with patented technology that enables digital ads to adapt to each unique situation and each individual for continuous up-to-the-instant relevance. Wylei is driving step-change marketing ROI’s for some of the biggest brands in the world like Marriott, Adidas, and Unilever.